Appleseed Fund has generated an annualized return of 7.19% per annum. We had a few big winners in 2015, namely Teva Pharmaceuticals ( TEVA ) and John B. Sanfilippo (JBSS), but the returns from these winners were more than offset by companies with
the timing of Momenta’s potential generic Copaxone launch, Teva ’s ability to aggressively convert patients to its new formulation ..... S. Food and Drug Administration approves a generic version. Teva already has over 60% of patients on the new formulation, a
upfront payment of USD 130 million and is eligible for up to USD 1,700 million in milestone payments through its alliance with Teva Pharmaceuticals, for its cardiovascular system programs now in phase III. Our fair value estimate is unchanged at AUD 7.00
Feb 11 (Reuters) - Israeli drugmaker Teva Pharmaceutical Industries Inc said it found some business practices and transactions could violate the U.S. Foreign Corrupt Practices Act.
* Teva seeks growth markets, complex generics, specialty drugs
* There might not be any generic Copaxone competition in 2015 but we assume there may be -CEO Further company coverage: (Reporting By Steven Scheer)
* Plans 7 drug launches in 2015 with $400 million of new revenue -CEO Further company coverage: (Reporting By Tova Cohen)
TEL AVIV, Feb 5 (Reuters) - Teva Pharmaceutical Industries reported quarterly profit that met analysts' estimates on Thursday and reaffirmed its earnings forecast for the full year.
changes to our fair value estimate for Teva after the company’s fourth-quarter ..... continue to drive modest earnings growth for Teva , but the high likelihood of a generic Copaxone ..... patents likely buys some additional time for Teva to transition patients to its newer formulation
Amgen has been mild, but should accelerate to eventual double-digit sales declines in the anemia and neutropenia franchises. Teva 's branded neutropenia drug Granix is still struggling to gain market share against Neupogen, and Amgen's upcoming launch